GlassScriptPhysician profile
Henry W Schoen
NPI 1639324247
$1,272.51
in general payments reported to CMS, 2019-2025
15 companies · $63.90 in 2025
The $63.90 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $407 · 2023: $323 · 2024: $238 · 2025: $63.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $238.57 | 2021-2025 | |
| Medtronic, INC. | $187.83 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.53 | 2021-2023 | Jardiance |
| Amgen INC. | $121.89 | 2021-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $115.62 | 2022-2025 | Camzyos |
| Pfizer INC. | $102.31 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $57.68 | 2023-2025 | Uptravi, Opsumit |
| Lantheus Medical Imaging, INC. | $48.61 | 2022-2023 | Definity |
| Genzyme Corporation | $44.77 | 2024 | |
| Merck Sharp & Dohme LLC | $31.39 | 2022-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.26 | 2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $20.09 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.94 | 2021 | |
| Cvrx, INC. | $17.02 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Schoen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.